Mubadala Bio
Mubadala Bio is a UAE-based life sciences company, wholly owned by Mubadala Investment Company, operating Integrated Biopharma (capsules, IV fluids, injectables, biologics) and Pharma Logistics (IDS and GMSC distribution) to serve hospitals, pharmacies, and government institutions across 100+ countries.
- Company typePrivate
- Founded2025
- HeadquartersDubai, United Arab Emirates
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Mubadala Bio does
Mubadala Bio is a UAE-headquartered life sciences company launched in 2025 and wholly owned by Mubadala Investment Company. It operates through two integrated verticals: Integrated Biopharma, which manufactures pharmaceuticals across soft gelatin capsules (Bioventure Healthcare, 1.5B capsule capacity), Non-PVC IV fluids and dialysis (WellPharma, 11M bag capacity), sterile Blow-Fill-Seal injectables (Gulf Inject), and biologics via a 10,000-litre DiabTec facility — the only one of its kind in the GCC; and Pharma Logistics, which runs end-to-end distribution through Al Ittihad Drug Store (IDS, serving 100% of UAE hospitals and 3,000+ pharmacies) and Global Medical Supply Chain (GMSC, integrated procurement, warehousing, cold-chain, and supply-chain management for ~190 healthcare facilities).
The business model is institutional B2B: products are sold via negotiated multi-year contracts to hospitals, healthcare systems, pharmacies, and government institutions in the UAE, with exports to 100+ countries enabled by EU GMP, US GMP, and cGMP certifications. Manufacturing revenue is product-based, while logistics revenue combines transaction-fee distribution services and value-add commercialization (regulatory, marketing, sales support) for global pharma brands.
The company serves government health authorities (e.g., UAE Ministry of Defense, University Hospital Sharjah), private hospital networks, retail pharmacies, and international buyers. Its strategic positioning is built on national drug security (UAE) and vertical integration spanning drug substance manufacturing to last-mile delivery, with 3,000+ FTEs across 10 sites in the UAE, Asia, Africa, and Europe.
Mubadala Bio firmographics
Firmographics- Name
- Mubadala Bio
- Legal name
- Mubadala Bio
- Website
- https://mubadalabio.ae
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Mubadala Bio is a UAE-based life sciences company, wholly owned by Mubadala Investment Company, operating Integrated Biopharma (capsules, IV fluids, injectables, biologics) and Pharma Logistics (IDS and GMSC distribution) to serve hospitals, pharmacies, and government institutions across 100+ countries.
- Ownership category
- akta.pro rank
Mubadala Bio industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Specialty Pharmaceutical Distributors (HLAIAJAB)
- akta.pro secondary industries
- Biologics & Biosimilars Distributors (HLAIAJAH), Pharmaceuticals & Biopharma (TLAIALAC), Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)
Keywords
Where Mubadala Bio is headquartered
LocationHeadquarters
- HQ city
- Dubai
- HQ country
- United Arab Emirates
- HQ region
- Middle East
Offices6 records
Markets served
Mubadala Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
Revenue model
- Pharmaceutical Manufacturing & Sales: Revenue generated from manufacturing and selling pharmaceutical products including soft gelatin capsules (Bioventure Healthcare), IV fluids and dialysis solutions (Wellpharma), sterile injectables (Gulf Inject), and biologic therapies (DiabTec). Products are sold to hospitals, pharmacies, healthcare providers, and exported to international markets across 100+ countries.
- Pharmaceutical Distribution & Logistics Services: Revenue from pharmaceutical logistics and distribution services through IDS and GMSC, providing medical procurement, warehousing, distribution, equipment servicing, and asset management to healthcare providers across the UAE. Services include full cold-chain management and 12–48-hour delivery.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Institutional B2B pricing — negotiated per contract |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels2 records
Mubadala Bio product offering
Product offeringCore offering
Mubadala Bio manufactures and distributes pharmaceutical products through two integrated verticals: Integrated Biopharma (pharmaceutical manufacturing including soft gelatin capsules via Bioventure Healthcare, IV fluids and dialysis solutions via Wellpharma, sterile injectables via Gulf Inject, and biologic therapies via DiabTec) and Pharma Logistics (pharmaceutical distribution, warehousing, and supply chain services via IDS and GMSC). The company serves hospitals, pharmacies, healthcare providers, and government institutions across the UAE, Asia, Africa, and Europe.
Differentiator
Problem solved
Functional benefit
Brands
- Integrated Biopharma: Vertical focused on advancing development and local production of high-quality, essential drugs by expanding UAE pharmaceutical manufacturing capabilities.
- Pharma Logistics
Products and services
- Soft Gelatin Capsules (Bioventure Healthcare)
- IV Fluids and Dialysis Solutions (Wellpharma)
- Sterile Injectables (Gulf Inject)
- Biologic Therapies (DiabTec)
- Pharmaceutical Distribution Services (IDS)
- Medical Supply Chain Services (GMSC)
Quantifiable outcome
- 2.5 billion capsules produced annually
- +6 more outcomes
Companies that use Mubadala Bio
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
Mubadala Bio technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Mubadala Bio partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core, secondary and minor.
- BiosiduscoreMubadala Bio signed a licensing and supply agreement with Biosidus at BIO International Convention 2026 in San Diego. The partnership is executed through DiabTec, Mubadala Bio's biologics facility in the UAE, supporting the localization of biologic therapies used in endocrinology, nephrology, and oncology. Biosidus provides biotechnology expertise while Mubadala Bio contributes local manufacturing capabilities, reinforcing national drug security.
- BayersecondaryIDS signed agreements with Bayer to broaden access to a wider portfolio of healthcare products and critical therapies across the UAE, as part of Mubadala Bio's Pharma Logistics expansion.
- GlobalpharmasecondaryIDS signed agreements with Globalpharma to broaden access to a wider portfolio of healthcare products and critical therapies across the UAE, as part of Mubadala Bio's Pharma Logistics expansion.
- Valeo HealthminorIDS signed an agreement with Valeo Health to enable access to wellness products through online channels, supporting IDS's strategy to reach consumers more easily and flexibly through e-commerce distribution.
- L-NutrasecondaryMubadala Bio's IDS signed an exclusive distribution and promotional agreement with L-Nutra at Make it in the Emirates 2026. IDS will exclusively market and distribute L-Nutra's longevity nutrition products, including ProLon and Fast Mimicking Diet products, across the UAE. This partnership reflects Mubadala Investment Company's prior strategic investment in L-Nutra and the establishment of a joint venture in Abu Dhabi for producing longevity-focused nutrition for the MENA region.
- M42coreM42 (global health leader powered by AI, technology, and genomics) and Mubadala Bio's GMSC signed an exclusive outsourcing agreement at Make it in the Emirates 2026. GMSC manages a fully integrated supply chain model across M42's healthcare network covering sourcing, procurement, demand planning, warehousing, distribution, and inventory management. The partnership strengthens medical supply chain resilience and operational efficiency across M42's network of world-class healthcare facilities.
- BorougesecondaryBorouge and Mubadala Bio partnered to advance UAE healthcare and life sciences manufacturing, announced May 2025. The partnership aims to strengthen domestic pharmaceutical production capabilities and support the UAE's broader healthcare and life sciences manufacturing ecosystem.
Scale indicators11 records
Recent moves8 records
Expansion highlights6 records
Mubadala Bio competitors and assessment
Company assessmentDirect peers
- Neopharma: UAE-based pharmaceutical manufacturer with capabilities across generics, biologics, and sterile manufacturing. Comparable to Mubadala Bio's manufacturing footprint in Abu Dhabi and GCC market positioning.
- Julphar (Gulf Pharmaceutical Industries): UAE-based pharmaceutical manufacturer producing generics, biosimilars, and consumer health products across multiple dosage forms. Directly comparable to Mubadala Bio's Integrated Biopharma vertical in geography, product mix, and institutional customer base; former employer of Mubadala Bio's Group CEO.
Broad incumbents
- Bayer: Global pharmaceutical and life sciences incumbent. Directly relevant as an existing distribution partner with IDS (Mubadala Bio) and as a broader category incumbent in pharmaceutical products.
- AstraZeneca: Global pharmaceutical company with leading biologics and oncology portfolios. Comparable as a partner candidate for DiabTec-style licensing arrangements and as an incumbent competitor in the regional biologics market.
- McKesson: Global pharmaceutical distribution and supply chain services leader. Comparable to Mubadala Bio's Pharma Logistics vertical in large-scale drug distribution, warehousing, and institutional supply chain services.
- Pfizer: Global pharmaceutical incumbent with broad portfolio across branded, generics, and biologics. Relevant as an incumbent competitor and partner counterpart (Bayer is a similar partner) for institutional tenders in the UAE.
Regional players
- Hikma Pharmaceuticals: Jordan-headquartered multinational pharmaceutical company with strong MENA and US generics, injectables, and biologics businesses. Comparable in regional MENA footprint, regulated manufacturing capabilities, and integrated supply chain model.
- SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation): Saudi Arabia-headquartered pharmaceutical manufacturer and distributor serving the GCC. Comparable regional pharma manufacturer with overlapping generics, injectables, and distribution operations, though Saudi-focused rather than UAE-anchored.
- Tabuk Pharmaceuticals: Saudi pharmaceutical manufacturer focused on generics and branded products across the MENA region. Comparable regional manufacturer with similar institutional customer base and regulatory certifications, though Saudi-anchored.
- Julphar Logistics / UAE Pharma Distribution Peers (Emirates Healthcare): UAE-based healthcare distribution and supply chain player serving hospitals and pharmacies. Comparable to Mubadala Bio's Pharma Logistics vertical in hospital and pharmacy distribution across the UAE.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
Mubadala Bio social profiles
Digital presenceMubadala Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mubadala Bio leadership team
Management profileNumber of profiles
Profiles11 records
Mubadala Bio subsidiaries and ownership
Company hierarchySubsidiaries6 records
Mubadala Bio funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mubadala Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mubadala Bio
What does Mubadala Bio do?
Mubadala Bio manufactures and distributes pharmaceutical products through two integrated verticals: Integrated Biopharma (pharmaceutical manufacturing including soft gelatin capsules via Bioventure Healthcare, IV fluids and dialysis solutions via Wellpharma, sterile injectables via Gulf Inject, and biologic therapies via DiabTec) and Pharma Logistics (pharmaceutical distribution, warehousing, and supply chain services via IDS and GMSC). The company serves hospitals, pharmacies, healthcare providers, and government institutions across the UAE, Asia, Africa, and Europe.
Is Mubadala Bio a public or private company?
Mubadala Bio is a private company. It is classified as state government owned and is currently operating.
When was Mubadala Bio founded?
Mubadala Bio was founded in 2025. It employs 51 to 100 people.
Where is Mubadala Bio based?
Mubadala Bio is headquartered in Dubai, United Arab Emirates, in the Middle East region.
How does Mubadala Bio make money?
Two revenue lines are on record. Pharmaceutical Manufacturing & Sales are the primary driver. The others are pharmaceutical Distribution & Logistics Services.
Who are Mubadala Bio's main competitors?
Direct peers on record are Neopharma and Julphar (Gulf Pharmaceutical Industries). Broad incumbents are Bayer, AstraZeneca, McKesson and Pfizer. Regional players are Hikma Pharmaceuticals, SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation), Tabuk Pharmaceuticals and Julphar Logistics / UAE Pharma Distribution Peers (Emirates Healthcare).
Does Mubadala Bio have an API?
No public API is recorded for Mubadala Bio.
What industry is Mubadala Bio in?
Mubadala Bio's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIAJAB, Specialty Pharmaceutical Distributors, with a secondary code of HLAIAJAH, Biologics & Biosimilars Distributors. Its NAICS code is 325412 and its SIC code is 5122.